PE20080339A1 - Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento - Google Patents

Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento

Info

Publication number
PE20080339A1
PE20080339A1 PE2007000780A PE2007000780A PE20080339A1 PE 20080339 A1 PE20080339 A1 PE 20080339A1 PE 2007000780 A PE2007000780 A PE 2007000780A PE 2007000780 A PE2007000780 A PE 2007000780A PE 20080339 A1 PE20080339 A1 PE 20080339A1
Authority
PE
Peru
Prior art keywords
modified
proteepine
coagulation factor
treatment
same
Prior art date
Application number
PE2007000780A
Other languages
English (en)
Inventor
Jorge Oyhenart
Xavier Gallet
Gilles Borrelly
Thierry Guyon
Manuel Vega
Lila Drittanti
Original Assignee
Nautilus Technology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nautilus Technology Llc filed Critical Nautilus Technology Llc
Publication of PE20080339A1 publication Critical patent/PE20080339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN POLIPEPTIDO DE FIX (FACTOR DE COAGULACION IX) MODIFICADO QUE CONSTA DE UNA MODIFICACION AMINOACIDICA EN UN POLIPEPTIDO DE FIX MADURO ESTABLECIDO EN SEQ ID NO:2 o 1035. LAS MODIFICACIONES AMINOACIDICAS CORRESPONDEN A MODIFICACIONES SELECCIONADAS ENTRE S174Q/F192I/D203Q, S174H/D186N/F192I Y T179Q/F192I/D203Q. DICHO POLIPEPTIDO MODIFICADO ESTA GLICOSILADO, CARBOXILADO, HIDROXILADO, SULFATADO, FOSFORILADO, ALBUMINADO O CONJUGADO A UN GRUPO FUNCIONAL POLIETILENGLICOL (PEG), MANTIENE LA ACTIVIDAD ADEMAS, AUMENTA LA RESISTENCIA A PROTEASAS EN EL TRACTO DIGESTIVO O EN EL FLUJO SANGUINEO COMPARADA CON EL POLIPEPTIDO NO MODIFICADO
PE2007000780A 2006-06-19 2007-06-19 Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento PE20080339A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81511306P 2006-06-19 2006-06-19

Publications (1)

Publication Number Publication Date
PE20080339A1 true PE20080339A1 (es) 2008-06-06

Family

ID=38834052

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000780A PE20080339A1 (es) 2006-06-19 2007-06-19 Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento

Country Status (6)

Country Link
US (2) US8383388B2 (es)
EP (4) EP2423305A1 (es)
CL (1) CL2012000063A1 (es)
PE (1) PE20080339A1 (es)
TW (1) TW200804416A (es)
WO (1) WO2007149406A2 (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
AU2005244271B2 (en) 2004-04-12 2010-04-08 Vertex Pharmaceuticals Incorporated Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
MX2008004693A (es) 2005-10-21 2008-09-03 Catalyst Biosciences Inc Proteasas modificadas que inhiben la activacion del complemento.
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
DK2046951T5 (da) * 2006-07-05 2012-01-23 Catalyst Biosciences Inc Proteasesreeningsmetoder og proteaser identificeret dermed
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EP2147096B1 (en) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
JP5613876B2 (ja) * 2007-10-15 2014-10-29 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 延長された半減期を備えるヒト第ｉｘ因子変異体
JP2011507919A (ja) * 2007-12-27 2011-03-10 バクスター・インターナショナル・インコーポレイテッド 修飾第ｉｘ因子
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
KR20110015551A (ko) * 2008-04-16 2011-02-16 바이엘 헬스케어 엘엘씨 제ｉｘ인자의 부위-지정 변형
WO2009137254A2 (en) * 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
US20110137011A1 (en) * 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
PL2293804T3 (pl) 2008-05-29 2014-03-31 Univ Bologna Alma Mater Studiorum Wirus opryszczki pospolitej (HSV) o zmodyfikowanym tropizmie, jego zastosowanie i sposób przygotowania
EP2149603A1 (en) * 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
IT1395980B1 (it) * 2009-05-06 2012-11-09 Simioni Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
DK2337849T3 (en) * 2008-09-15 2018-10-01 Uniqure Biopharma B V FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF
IT1394177B1 (it) * 2008-09-15 2012-06-01 Simioni Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
JP2012526840A (ja) * 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
ES2524974T3 (es) 2009-06-25 2014-12-16 The University Of North Carolina At Chapel Hill Moléculas del Factor VII quimérico
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2011011841A1 (en) * 2009-07-31 2011-02-03 Fundação Hemocentro de Ribeirão Preto Human blood coagulation factor ix recombinant protein, composition, use of a factor ix recombinant protein, use of a composition, method of obtaining human blood coagulation factor ix recombinant protein and use of the factor ix recombinant protein
SG178119A1 (en) * 2009-07-31 2012-03-29 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
EP2590668A4 (en) 2010-07-09 2014-04-02 Biogen Idec Hemophilia Inc FACTOR IX POLYPEPTIDES AND METHOD OF USE THEREOF
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP5791022B2 (ja) * 2010-12-13 2015-10-07 学校法人日本大学 細胞遊走調節剤
WO2012149463A1 (en) * 2011-04-29 2012-11-01 The University Of North Carolina At Chapel Hill Chimeric factor vii molecules with enhanced half life and methods of use
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
EP2842966B1 (en) * 2012-04-27 2018-08-15 Nihon University Therapeutic agent for epithelial and endothelial injury
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EA028865B1 (ru) 2012-07-25 2018-01-31 Каталист Биосайенсиз, Инк. Модифицированные полипептиды фактора х и их применение
US20150252345A1 (en) 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
CN112661863A (zh) 2012-11-20 2021-04-16 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
PT3889173T (pt) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc Gene do fator viii otimizado
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
US10265405B2 (en) 2014-11-18 2019-04-23 Board Of Regents, The University Of Texas System Polymers for delivery of factor VIII and/or factor IX
TWI806034B (zh) * 2015-05-06 2023-06-21 美商阿尼拉製藥公司 第十二因子（哈格曼因子）（Ｆ１２）、激肽釋放素Ｂ、血漿（夫列契因子）１（ＫＬＫＢ１）及激肽原１（ＫＮＧ１）ｉＲＮＡ組成物及其使用方法
EP3988113A1 (en) 2015-06-19 2022-04-27 OPKO Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
RS63548B1 (sr) 2016-02-01 2022-09-30 Bioverativ Therapeutics Inc Optimizovani geni faktora viii
KR102510256B1 (ko) * 2016-06-27 2023-03-16 다케다 야쿠힌 고교 가부시키가이샤 주사기 안정화기
BR112019000610A2 (pt) 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
US11708570B2 (en) 2016-07-27 2023-07-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating Factor IX function
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP2020505424A (ja) 2017-01-31 2020-02-20 バイオベラティブ セラピューティクス インコーポレイテッド 因子ｉｘ融合タンパク質ならびにその製造および使用方法
NZ759034A (en) * 2017-05-22 2023-07-28 Takeda Pharmaceuticals Co Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
CN112203646A (zh) 2018-04-04 2021-01-08 西吉隆医疗股份有限公司 可植入颗粒和相关方法
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
CN113227385A (zh) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
AU2019360270A1 (en) 2018-10-18 2021-05-27 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
GB201817810D0 (en) * 2018-10-31 2018-12-19 Ucl Business Plc Modified factor IX polypeptides
JP2022525660A (ja) * 2019-03-19 2022-05-18 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｉｘ因子バリアントおよび治療でのその使用
CN114008069A (zh) 2019-04-17 2022-02-01 科迪亚克生物科学公司 外来体和aav的组合物
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
CN111647625A (zh) * 2019-12-25 2020-09-11 深圳三智医学科技有限公司 一种提高人凝血因子ix表达水平的方法
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
US20230374484A1 (en) * 2020-10-30 2023-11-23 Expression Therapeutics, Llc Clotting Factor Variants and Their Use
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
JP2584443B2 (ja) 1985-04-22 1997-02-26 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 活性化▲ｉ▼▲ｘ▼因子の高収率産生
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US6027913A (en) 1988-01-28 2000-02-22 Sommer; Steven S. Nucleic acid amplification with direct sequencing
FR2638643B1 (fr) 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU1398595A (en) 1993-12-22 1995-07-10 Temple University - Of The Commonwealth System Of Higher Education Peptide analogs of the factor ixa platelet binding site
EP0917566B1 (de) 1996-06-11 2004-09-22 Roche Diagnostics GmbH Rekombinante blutgerinnungsproteasen
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
ATE455552T1 (de) * 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US20030073169A1 (en) 1997-09-18 2003-04-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20050250688A1 (en) 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6624289B1 (en) 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
FR2802645B1 (fr) 1999-12-16 2002-03-08 Meillat Roland Methode d'evaluation de la performance d'un ensemble d'agents biologiques dans des cellules cibles vivantes et ses applications
US20040102388A1 (en) 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
FR2808804B1 (fr) 2000-05-09 2002-08-02 Nautilus Biotech Procede de determination du titre d'agents biologiques en temps reel dans des cellules cibles vivantes et ses applications
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
EP1418810A4 (en) 2001-08-03 2006-08-02 Us Gov Health & Human Serv TREATMENT OF HEMOPHILIA ORAL
US20030129203A1 (en) 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
JP2005501547A (ja) 2001-09-04 2005-01-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾された第ｉｘ因子
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040126856A1 (en) 2002-01-23 2004-07-01 Bajaj Paul S. Factor ixa: factor Vllla interaction and methods therefor
US20030224404A1 (en) 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20060020396A1 (en) 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
EP1539960B1 (en) 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
WO2004022747A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060024289A1 (en) 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
ZA200502867B (en) 2002-10-02 2007-09-26 Catalyst Biosciences Inc Methods of generating and screening for proteases with altered specificity
DK1644504T3 (da) 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2005244271B2 (en) 2004-04-12 2010-04-08 Vertex Pharmaceuticals Incorporated Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1
WO2005100556A2 (en) 2004-04-12 2005-10-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
KR20070085227A (ko) 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
KR20070043051A (ko) 2004-08-17 2007-04-24 쳇엘베 베링 게엠베하 변형된 비타민 ｋ 의존적 폴리펩타이드
KR101249287B1 (ko) 2004-09-03 2013-04-01 크리어빌리스 쎄라퓨틱스 에스.피.에이. 인간 및 비­인간 ｈｍｇｂ１ ｂｏｘ­ａ의 단백질분해효소내성 돌연변이 및 그들의 치료／진단 용도
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CA2607806A1 (en) 2005-05-04 2006-11-16 Nautilus Biotech, S.A. Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
US20070042494A1 (en) 2005-05-31 2007-02-22 Tal Kafri Heterologous retroviral packaging system
US20070021421A1 (en) 2005-07-25 2007-01-25 Hampton Thomas G Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis
MX2008004693A (es) 2005-10-21 2008-09-03 Catalyst Biosciences Inc Proteasas modificadas que inhiben la activacion del complemento.
US20080038224A1 (en) 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
CN104593348A (zh) 2006-05-24 2015-05-06 诺沃—诺迪斯克保健股份有限公司 具有延长的体内半寿期的因子ix类似物
DK2046951T5 (da) 2006-07-05 2012-01-23 Catalyst Biosciences Inc Proteasesreeningsmetoder og proteaser identificeret dermed
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
US7605753B2 (en) * 2007-01-23 2009-10-20 Joakim Landmark Wireless communication device and method for reducing interference in a receiver
EP2147096B1 (en) 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2009137254A2 (en) * 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
US20110137011A1 (en) * 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix

Also Published As

Publication number Publication date
EP2423307A1 (en) 2012-02-29
WO2007149406A9 (en) 2008-03-13
US8383388B2 (en) 2013-02-26
TW200804416A (en) 2008-01-16
EP2423305A1 (en) 2012-02-29
EP2084274A2 (en) 2009-08-05
CL2012000063A1 (es) 2012-08-24
WO2007149406A8 (en) 2008-09-25
US20080102115A1 (en) 2008-05-01
WO2007149406A3 (en) 2008-07-10
EP2423306A1 (en) 2012-02-29
WO2007149406A2 (en) 2007-12-27
US20130243855A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
PE20080339A1 (es) Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
BR112012011332A2 (pt) agentes direcionados para gadd45beta
PE20110426A1 (es) Polipeptidos g-csf bovinos modificados
AR022578A1 (es) Peptidos artificiales que tienen actividad superficial y el uso de los mismos en la preparacion de un tensioactivo artificial
AR069830A1 (es) Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos
BRPI0514411A (pt) formulação, e, método de produzir uma formulação
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
BR122016022033B8 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
BRPI0411172A (pt) peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
BRPI0512396A (pt) polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
UY27720A1 (es) Aroilpiridinonas monocíclicas,
HRP20050024A2 (en) Pegylated t20 polypeptide
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
HRP20090245T1 (en) Pyy agonists and uses thereof
UY29088A1 (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
ES2185595T3 (es) Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
ECSP044996A (es) Agentes de contraste de objetivo multimérico basado en péptido
DK2162462T3 (da) Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
NO20093064L (no) Templatfikserte peptidhermere
ECSP10010729A (es) Péptidos dirigidos a crkl

Legal Events

Date Code Title Description
FA Abandonment or withdrawal